Your browser doesn't support javascript.
loading
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Byrd, John C; Wierda, William G; Schuh, Anna; Devereux, Stephen; Chaves, Jorge M; Brown, Jennifer R; Hillmen, Peter; Martin, Peter; Awan, Farrukh T; Stephens, Deborah M; Ghia, Paolo; Barrientos, Jacqueline; Pagel, John M; Woyach, Jennifer A; Burke, Kathleen; Covey, Todd; Gulrajani, Michael; Hamdy, Ahmed; Izumi, Raquel; Frigault, Melanie M; Patel, Priti; Rothbaum, Wayne; Wang, Min Hui; O'Brien, Susan; Furman, Richard R.
Afiliação
  • Byrd JC; Comprehensive Cancer Center, The Ohio State University, Columbus, OH.
  • Wierda WG; The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Schuh A; Department of Oncology, University of Oxford, Oxford, United Kingdom.
  • Devereux S; King's College Hospital, NHS Foundation Trust, London, United Kingdom.
  • Chaves JM; Northwest Medical Specialties, Tacoma, WA.
  • Brown JR; Dana-Farber Cancer Institute, Boston, MA.
  • Hillmen P; St. James's University Hospital, Leeds, United Kingdom.
  • Martin P; Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, NY.
  • Awan FT; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.
  • Stephens DM; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
  • Ghia P; Università Vita-Salute San Raffaele, Milan, Italy.
  • Barrientos J; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.
  • Pagel JM; School of Medicine, Hofstra/Northwell, Hempstead, NY.
  • Woyach JA; Swedish Cancer Institute, Seattle, WA.
  • Burke K; Comprehensive Cancer Center, The Ohio State University, Columbus, OH.
  • Covey T; Oncology iMED, AstraZeneca, Boston, MA.
  • Gulrajani M; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA; and.
  • Hamdy A; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA; and.
  • Izumi R; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA; and.
  • Frigault MM; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA; and.
  • Patel P; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA; and.
  • Rothbaum W; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA; and.
  • Wang MH; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA; and.
  • O'Brien S; Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA; and.
  • Furman RR; Chao Family Comprehensive Cancer Center, UC Irvine Health, University of California, Irvine, CA.
Blood ; 135(15): 1204-1213, 2020 04 09.
Article em En | MEDLINE | ID: mdl-31876911
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazinas / Benzamidas / Leucemia Linfocítica Crônica de Células B / Inibidores de Proteínas Quinases / Tirosina Quinase da Agamaglobulinemia / Recidiva Local de Neoplasia / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2020 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazinas / Benzamidas / Leucemia Linfocítica Crônica de Células B / Inibidores de Proteínas Quinases / Tirosina Quinase da Agamaglobulinemia / Recidiva Local de Neoplasia / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2020 Tipo de documento: Article País de publicação: Estados Unidos